LIÈGE, Belgium, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for the treatment of severe autoimmune diseases, today reported positive biomarker data from a planned interim analysis of its Phase 2 study, IMCY-0098 Proof of ACtion in Type 1 Diabetes (T1D) (IMPACT), evaluating the Company’s lead candidate IMCY-0098, a proinsulin-derived ImotopeTM engineered to treat and prevent T1D. The Company also reported that the study reached the midpoint of recruitment and both the U.S. Food and Drug Administration (FDA) and Australian Therapeutics Goods Administration (TGA) approved the Company’s Investigational New Drug (IND) application to initiate the study in these two countries.
Ultra-small nanostructured lipid carriers (usNLCs) have been hypothesized to promote site-specific glioblastoma (GB) drug delivery. Envisioning a multitarget purpose towards tumor cells and microenvironment, a surface-bioconjugated usNLC prototype is herein presented. The comeback of co-delivery by repurposing atorvastatin and curcumin, as complementary therapy, was unveiled and characterized, considering colloidal properties, stability, and drug release behavior.
BASKING RIDGE, N.J., Feb. 13, 2019 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company with multiple development programs targeting select cardiovascular indications and autoimmune disease, today announced top-line results from The Sanford Project: T-Rex Study, a prospective, randomized, placebo-controlled, double-blind Phase 2a clinical trial of 110 subjects to evaluate the safety and efficacy of the Company’s CLBS03 as a treatment for recent-onset type 1 diabetes (“T1D”) in adolescents.